Peptidi e Proteine
I peptidi sono corte catene di amminoacidi legate da legami peptidici, mentre le proteine sono catene di amminoacidi più lunghe e complesse, capaci di assumere strutture tridimensionali funzionali. Entrambi i tipi di composti sono essenziali per diverse funzioni biologiche, come la catalisi delle reazioni (enzimi), la difesa immunitaria (anticorpi) e la segnalazione cellulare. Le proteine hanno una struttura gerarchica che comprende la sequenza di amminoacidi e le strutture secondaria, terziaria e quaternaria. I peptidi vengono utilizzati in terapie farmaceutiche e cosmetiche per le loro specifiche proprietà biologiche, ad esempio nel trattamento di malattie metaboliche o nel miglioramento della rigenerazione cellulare. Le proteine, invece, trovano applicazioni in biotecnologia, nutrizione e medicina rigenerativa.
Presso CymitQuimica, offriamo peptidi e proteine di alta purezza per la ricerca in biotecnologia e applicazioni terapeutiche.
Trovati 3129 prodotti di " Peptidi e Proteine"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
N-Glycylproline
CAS:<p>Applications N-Glycylproline was found to exhibit anti-ischemic effects on the metabolism of neuroactive amino acids and indices of energy turnover in the neocortex of rats after experimental brain ischemia.<br>References Bashun, Z.N., et al.: Neurochem. J., 7, 39 (2013);<br></p>Formula:C7H12N2O3Colore e forma:NeatPeso molecolare:172.182Lisinopril Cyclohexyl Analogue
CAS:Prodotto controllato<p>Impurity Lisinopril EP Impurity F<br>Applications Lisinopril Cyclohexyl Analogue (Lisinopril EP Impurity F) is a Lisinopril (L468985) impurity.<br>References Paraskevas, G., et al.: J. Pharm. Biomed. Anal., 29, 865 (2002),<br></p>Formula:C21H37N3O5Colore e forma:NeatPeso molecolare:411.54Teduglutide
CAS:<p>Teduglutide (ALX-0600) is a glucagon-like peptide-2 analog that increases intestinal absorption and can be used in research on short bowel syndrome (SBS).</p>Formula:C164H252N44O55SPurezza:98.08%Colore e forma:SolidPeso molecolare:3752.08DL-Methionyl-DL-methionine
CAS:Prodotto controllatoFormula:C10H20N2O3S2Colore e forma:NeatPeso molecolare:280.4(2R,4R)-Sacubitril
CAS:<p>Applications (2R,4R)-Sacubitril is an impurity of Sacubitril (S080895) which is an antihypertensive drug used in combination with valsartan.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References McMurray, J., et al.: N. Eng. J. Med., 371 (2014);<br></p>Formula:C24H29NO5Colore e forma:NeatPeso molecolare:411.4914-Methylbenzenesulfonic Acid Monohydrate
CAS:Prodotto controllato<p>Impurity Lisinopril EP Impurity B/ Anastrozole EP Impurity F<br>Applications 4-Methylbenzenesulfonic Acid Monohydrate (Lisinopril EP Impurity B) is used in the synthesis of resveratrol. Also used in the synthesis of oxane derivatives as antimalarial agents.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Davis, M. et al.: Org. Prep. Proc. Int., 45, 304 (2013); Wang, X. et al.: J. Med. Chem., 56, 2547 (2013);<br></p>Formula:C7H8O3S·H2OColore e forma:WhitePeso molecolare:190.223,3',5'-Triiodo-L-thyronine
CAS:Formula:C15H12I3NO4Colore e forma:Light Beige To GreyPeso molecolare:650.97L-Thioproline
CAS:<p>Applications L-Thioproline is used to create a monolayer on gold electrodes for the determination Copper(II). L-Thioproline has shown to be an effect inhibitor of proline absorption in Saccharomyces chevalieri.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Cui, X., et. al.: Sci. China Chem., 53, 257 (2010); Magana-Schwenchke, N., Schwencke, J.: BBA-Biomembranes, 173, 313 (1969)<br></p>Formula:C4H7NO2SColore e forma:NeatPeso molecolare:133.17Desisobutyl-n-butyl Bortezomib
CAS:<p>Impurity Bortezomib N-Pentyl Impurity<br>Applications Desisobutyl-n-butyl Bortezomib is an impurity of Bortezomib (B675700). Bortezomib impurity 5.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Lin, G., et al.: J. Biol. Chem., 283, 34423 (2008);<br></p>Formula:C19H25BN4O4Colore e forma:NeatPeso molecolare:384.24N-Pyrazinylcarbonyl-L-phenylalanine Methyl Ester
CAS:<p>Applications Used for the synthesis of Bortezomib from L-phenylalanine via dipeptidyl boronic acid ester intermediates.<br>References Zhu, Y., et al.: J. Med. Chem., 52, 4192 (2009),<br></p>Formula:C15H15N3O3Colore e forma:NeatPeso molecolare:285.30Lisinopril (S,S,R)-Diketopiperazine (~90%)
CAS:<p>Impurity Lisinopril EP Impurity D<br>Stability Hygroscopic<br>Applications Lisinopril (S,S,R)-Diketopiperazine (Lisinopril EP Impurity D) is an impurity of Lisinopril (L468985), an orally active angiotensin-converting enzyme (ACE) inhibitor (1).<br>References 1. Goa, K. et al.: Drugs. 1996 Oct;52(4):564-88.<br></p>Formula:C21H29N3O4Purezza:~90%Colore e forma:White To Off-WhitePeso molecolare:387.47β-Hydroxy Thyroxine (>90%)
CAS:Prodotto controllato<p>Impurity Levothyroxine beta-Hydroxy Impurity / Levothyroxine beta-Hydroxy T4 Impurity<br>Applications It has been prepared for testing as possible antithyroid. It showed some thyromimetic activity.<br>References Wawzone, S., et al.: J. Med. Chem., 6, 442 (1963),<br></p>Formula:C15H11I4NO5Purezza:>90%Colore e forma:NeatPeso molecolare:792.87Dihydro Cyclosporin A
CAS:Prodotto controllato<p>Applications A Cyclosporin A (C988900) analog, an immunosuppressant.<br>References Emmer, G., et al.: J. Med. Chem., 37, 1918 (1994), High, K., et al.: J. Biol. Chem., 269, 9105 (1994),<br></p>Formula:C62H113N11O12Colore e forma:WhitePeso molecolare:1204.63N-[(1S)-2-[(3-Methylbutyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-2-pyrazinecarboxamide
CAS:Prodotto controllatoFormula:C19H24N4O2Colore e forma:White To Off-WhitePeso molecolare:340.41951-Nitrosopyrrolidine-2-carboxylic Acid
CAS:Prodotto controllato<p>Applications 1-nitrosopyrrolidine-2-carboxylic acid (cas# 2571-28-0) is a useful research chemical.<br></p>Formula:C5H8N2O3Colore e forma:NeatPeso molecolare:144.129(R)-Lisinopril Sodium Salt
CAS:<p>Applications R,S,S-Isomer of Lisinopril (L468985).<br>References Goa, K.L., et al.: Drugs, 52, 564 (1996), Chaturvedi, N., et al.: Lancet, 351, 28 (1998)<br></p>Formula:C21H31N3NaO5Colore e forma:NeatPeso molecolare:428.48rhPTH (1-30) Trifluoroacetic Acid Salt Hydrate
Prodotto controllato<p>Impurity Teriparatide Impurity<br>Applications A fragment of human parathyroid hormone (hPTH) peptide sequence containing the 30 N-terminal residues of hPTH.<br>References Niall, et al.: Proc. Natl. Acad. Sci., 71, 384 (1974);<br></p>Formula:C157H260N48O46S2•x(C2HF3O2)•y(H2O)Colore e forma:NeatPeso molecolare:3620.171140218Sacubitril Calcium
CAS:<p>Applications Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure.<br>References McMurray, J., et al.: N. Eng. J. Med., 371 (2014)<br></p>Formula:C24H28NOCa2Colore e forma:NeatPeso molecolare:430.52Carfilzomib (2S,4R)-Diol
Prodotto controllato<p>Applications Carfilzomib (2S,4R)-Diol is a derivative of Carflizomib (C183460), a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.<br>References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);<br></p>Formula:C40H59N5O8Colore e forma:NeatPeso molecolare:737.93L-Methionine-34S
CAS:<p>Applications Labelled L-Methionine, an essential aminoacid for human development. Hepatoprotectant; antidote (acetominophen poisoning); urinary acidifier.<br>References Benevenga, N.J., et al.: J. Agric. Food Chem., 22, 2 (1974), Fleisher, L.D., et al.: Clin. Endocrinol. Metab., 3, 37 (1974), Meinnel, T., et al.: Biochimie, 75, 1061 (1993),<br></p>Formula:C5H11NO234SColore e forma:NeatPeso molecolare:151.11N-Acetyl-L-carnosine
CAS:Prodotto controllato<p>Applications Used in the treatment of cataracts and in the treatment of UV-induced immunosuppression. May act with with lipoic acid (L468725) to reverse age-related metabolic decline and also the indicies of oxidative stress.<br>References Babizhayev, M., et al.: J. Pharmacol. Toxicol., 1, 201 (2006), Min, J., et al.: J. Neurosci. Res., 86, 2984 (2008), Babizhayev, M., et al.: J. Drug Target., 17, 36 (2009); Hagen et. al, PNAS 99: 1870 (2002); Liu et. al, PNAS 99, 2356 (2002)<br></p>Formula:C11H16N4O4Colore e forma:Off-WhitePeso molecolare:268.276-Perdeoxy-6-perchloro-γ-cyclodextrin, >90%
CAS:Formula:C48H72Cl8O32Purezza:>90%Colore e forma:NeatPeso molecolare:1444.69(S)-Tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetic Acid
CAS:Prodotto controllatoFormula:C9H16N2O3Colore e forma:NeatPeso molecolare:200.23GSK1904529A
CAS:<p>GSK1904529A (GSK 4529) is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .</p>Formula:C44H47F2N9O5SPurezza:98.2% - 99.38%Colore e forma:SolidPeso molecolare:851.96D-Ser(8)-Semaglutide
<p>D-Ser(8)-Semaglutide is a semaglutide impurity. The amino acid at position 8 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molD-His(1)-Semaglutide
<p>D-His(1)-Semaglutide is a semaglutide impurity. The amino acid at position 1 has been replaced by the D-form of the amino acid D-histidine (D-His). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molSemaglutide Impurity 51 (D-Thr 7)
<p>D-Thr(7)-Semaglutide is a semaglutide impurity. The amino acid at position 7 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molDes-His(1)-Semaglutide
<p>Des-His(1)-semaglutide is a semaglutide-related impurity. This des-amino acid form has the histidine (His) amino acid from position 1 removed from the peptide chain. Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist used for managing type 2 diabetes and obesity.</p>Formula:C181H284N42O58Peso molecolare:3,976.5 g/molSemaglutide Impurity 54 (D-Ala 18)
<p>D-Ala(18)-Semaglutide is a semaglutide impurity. The amino acid at position 18 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molSemaglutide Impurity 29 (β-Asp-9)
<p>Beta-Asp-(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the beta-aspartic acid (also known as isoaspartic, isoAsp, β-Asp or beta-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molLinear Semaglutide
<p>Linear semaglutide, or simply L-Sema, is the semaglutide compound without the lipid side chain modification. It is essentially a linear version of the peptide.</p>Formula:C152H230N42O47Peso molecolare:3,397.76 g/molD-Thr(5)-Semaglutide
<p>D-Thr(5)-Semaglutide is a semaglutide impurity. The amino acid at position 5 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/mol(R)-3-Methyl-1-(pyrazine- 2-carboxamido)butylboronic acid
<p>The compound is a drug product, analytical, and research material. The molecule has been synthesized and purified by the company's chemists. It is not an API impurity but an impurity standard for HPLC. This compound is a synthetic chemical that does not occur naturally in any living organism. It has been developed for use in drug development and research. The compound was custom synthesized by the company's chemists to meet customer demand for high purity standards of this compound. It is used as a pharmacopoeia standard for HPLC analysis and drug development.</p>Purezza:Min. 95%D-Phe(6)-Semaglutide
<p>D-Phe(6)-Semaglutide is a semaglutide impurity. The amino acid at position 6 has been replaced by the D-form of the amino acid D-phenylalanine (D-Phe). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molD-Ser(11)-Semaglutide
<p>D-Ser(11)-Semaglutide is a semaglutide impurity. The amino acid at position 11 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/mol3,3',5,5'-Tetraiodothyroformic acid
CAS:<p>Cymit Quimicaetic beta-D-glucosiduronic acid</p>Formula:C13H6I4O4Purezza:Min. 95 Area-%Colore e forma:Off-White PowderPeso molecolare:733.8 g/molD-Ala-(19)-Semaglutide
<p>D-Ala(19)-Semaglutide is a semaglutide impurity. The amino acid at position 19 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molD-Ser-(12)-Semaglutide
<p>D-Ser(12)-Semaglutide is a semaglutide impurity. The amino acid at position 12 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molSemaglutide Impurity 101 (D-Glu 3)
<p>D-Glu(3)-Semaglutide is a semaglutide impurity. The amino acid at position 3 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molSemaglutide Impurity 59
<p>D-Arg(28)-Semaglutide is a semaglutide impurity. The amino acid at position 28 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molBortezomib intermediate I
CAS:<p>Bortezomib intermediate I is a metabolite of bortezomib, which is a research and development drug product. Bortezomib intermediate I is an impurity standard for bortezomib. Bortezomib intermediate I can be synthesized from the corresponding compound. It is an analytical standard used in pharmacopoeia and can be used as an API impurity or synthetic material in drug development. Bortezomib intermediate I has a high purity, natural origin, and a niche application. CAS No. 1248339-44-7</p>Formula:C25H36BN5O4Purezza:Min. 95%Colore e forma:White PowderPeso molecolare:481.4 g/molD-Val(10)-Semaglutide
<p>D-Val(10)-Semaglutide is a semaglutide impurity. The amino acid at position 10 has been replaced by the D-form of the amino acid D-valine (D-Val). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molDes-Glu(3)-Semaglutide
<p>Des-Glu(3)-semaglutide is a semaglutide-related impurity. This des-amino acid form has got the glutamic acid or glutamate (Glu) amino acid from position 3 removed from the peptide chain. Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist used for managing type 2 diabetes and obesity.</p>Formula:C182H284N44O56Peso molecolare:3,984.53 g/molLisinopril EP Impurity E
CAS:<p>Lisinopril EP Impurity E is an impurity of lisinopril, which is a prescription drug used to treat high blood pressure. This impurity was found in a preparative high performance liquid chromatography (HPLC) and mass spectroscopy analysis of the drug. The molecular weight of Lisinopril EP Impurity E was determined to be 317.2 amu, which corresponds to the molecular formula C7H13NO2. The FT-IR spectrum showed that this impurity has an ammonium group at 1859 cm-1 and butanoic acid at 1647 cm-1.</p>Formula:C21H31N3O5Purezza:Min. 98 Area-%Colore e forma:PowderPeso molecolare:405.49 g/molSemaglutide Impurity 56 (D-Glu 21)
<p>D-Glu(21)-Semaglutide is a semaglutide impurity. The amino acid at position 21 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/mol(S,E)-N-(1-(3-Methylbut-1-enylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide
CAS:<p>R-N-(1-(3-methylbut-1-enyl)-1-oxo-3-phenylpropan-2-yl) pyrazine-2-carboxamide is a drug product that is used for the treatment of bacterial infections. The compound is an impurity in the synthesis of other compounds and is also used as an analytical standard. It is synthesized from commercially available starting materials and through custom synthesis. R-N-(1-(3-methylbut-1-enyl)-1--oxo--3--phenylpropan--2--yl)pyrazine--2--carboxamide has been shown to be metabolized by CYP450 enzymes, which are responsible for the metabolism of many drugs. R-(1-(3Methylbut 1Enylamino)-1Oxo 3Phenylpropan 2Yl)Pyrazine 2Carboxamide has not been evaluated as a drug product and therefore does not</p>Formula:C19H22N4O2Purezza:Min. 95%Peso molecolare:338.4 g/molD-Ala(24)-Semaglutide
<p>D-Ala(24)-Semaglutide is a semaglutide impurity. The amino acid at position 24 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molSemaglutide Impurity 60 (D-Arg 30)
<p>D-Arg(30)-Semaglutide is a semaglutide impurity. The amino acid at position 30 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/molD-Asp(9)-Semaglutide
<p>D-Asp(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the D-form of the amino acid D-aspartic acid (D-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Peso molecolare:4,113.64 g/mol
![N-[(1S)-2-[(3-Methylbutyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-2-pyrazinecarboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTR%2Fthumb-webp%2FM291300.webp&w=3840&q=75)
